NCT05745363View on ClinicalTrials.gov

Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Differentiated Thyroid Cancer
Interventions
DRUG

AL2846 capsule

AL2846 is a multi-target tyrosine kinase inhibitor

Trial Locations (4)

330029

RECRUITING

Jiangxi Cancer Hospital, Nanchang

410013

RECRUITING

Hunan Cancer Hospital, Changsha

541001

RECRUITING

Affiliated Hospital Of Guilin Medical University, Guilin

650011

RECRUITING

Yunnan Cancer Hospital, Kunming

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY